EP4035656A1 — Method and composition for treating ocular hypertension and glaucoma
Assigned to Santen Pharmaceutical Co Ltd · Expires 2022-08-03 · 4y expired
What this patent protects
The present invention relates to the use of tafluprost for the manufacture of an ophthalmic aqueous solution for the treatment of ocular hypertension and glaucoma, wherein said ophthalmic solution comprises 0.0010-0.0025% w/v tafluprost, 0.075% w/v polysorbate 80, 0.005-0.2% w/v …
USPTO Abstract
The present invention relates to the use of tafluprost for the manufacture of an ophthalmic aqueous solution for the treatment of ocular hypertension and glaucoma, wherein said ophthalmic solution comprises 0.0010-0.0025% w/v tafluprost, 0.075% w/v polysorbate 80, 0.005-0.2% w/v stabilizing agent, and substantially no preservatives in a single dose or unit dose container consisting essentially of polyethylene.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.